miR-29b inhibits the progression of multiple myeloma through downregulating FOXP1

References

• Röllig C, Knop S, Bornhäuser M. Multiple myeloma. The Lancet. 2015;385(9983):2197–2208. doi: 10.1016/S0140-6736(14)60493-1
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111(6):2962–2972. doi: 10.1182/blood-2007-10-078022
   PubMed Web of Science ®Google Scholar
• Umezu T, Tadokoro H, Azuma K, et al. Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 2014;124(25):3748–3757. doi: 10.1182/blood-2014-05-576116
   PubMed Web of Science ®Google Scholar
• Leaf RK, Cho HJ, Avigan D. Immunotherapy for multiple myeloma, past, present, and future: monoclonal antibodies, vaccines, and cellular therapies. Curr Hematol Malig Rep. 2015;10(4):395–404. doi: 10.1007/s11899-015-0283-0
   PubMed Web of Science ®Google Scholar
• Maes A, Menu E, Veirman K, et al. The therapeutic potential of cell cycle targeting in multiple myeloma. Oncotarget. 2017;8(52):90501–90520. doi: 10.18632/oncotarget.18765
   PubMedGoogle Scholar
• Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22–32. doi: 10.1038/leu.2009.236
   PubMed Web of Science ®Google Scholar
• Katoh M, Igarashi M, Fukuda H, et al. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2013;328(2):198–206. doi: 10.1016/j.canlet.2012.09.017
   PubMed Web of Science ®Google Scholar
• Hu Z, Zhu L, Tan M, et al. The expression and correlation between the transcription factor FOXP1 and estrogen receptors in epithelial ovarian cancer. Biochimie. 2015;109:42–48. doi: 10.1016/j.biochi.2014.12.001
   PubMed Web of Science ®Google Scholar
• Hu Z, Zhu L, Gao J, et al. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis. Tumour Biol. 2015;36(9):7269–7275. doi: 10.1007/s13277-015-3383-5
   PubMedGoogle Scholar
• Cui R, Guan Y, Sun C, et al. A tumor-suppressive microRNA, miR-504, inhibits cell proliferation and promotes apoptosis by targeting FOXP1 in human glioma. Cancer Lett. 2016;374(1):1–11. doi: 10.1016/j.canlet.2016.01.051
   PubMed Web of Science ®Google Scholar
• Oskay HS. FOXP1 enhances tumor cell migration by repression of NFAT1 transcriptional activity in MDA-MB-231 cells. Cell Biol Int. 2017;41(1):102–110. doi: 10.1002/cbin.10702
   PubMed Web of Science ®Google Scholar
• Lagosquintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–858. doi: 10.1126/science.1064921
   PubMed Web of Science ®Google Scholar
• Wilczynska A, Bushell M. The complexity of miRNA-mediated repression. Cell Death Differ. 2015;22(1):22–33. doi: 10.1038/cdd.2014.112
   PubMed Web of Science ®Google Scholar
• Esquelakerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–269. doi: 10.1038/nrc1840
   PubMed Web of Science ®Google Scholar
• Reddy KB. MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015;15(1):167–166. doi: 10.1186/s12935-015-0185-1
   Web of Science ®Google Scholar
• Yan B, Guo Q, Fu F, et al. The role of miR-29b in cancer: regulation, function, and signaling. Oncotargets Ther. 2015;8(default):539–548.
   PubMed Web of Science ®Google Scholar
• Nguyen T, Kuo C, Nicholl MB, et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics. 2011;6(3):388–394. doi: 10.4161/epi.6.3.14056
   PubMed Web of Science ®Google Scholar
• Leva GD, Garofalo M, Croce CM. MicroRNAs in cancer. Annual Rev Pathol. 2014;9(1):287–314. doi: 10.1146/annurev-pathol-012513-104715
   PubMed Web of Science ®Google Scholar
• Morelli E, Leone E, Cantafio ME, et al. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 2015;29(11):2173–2183. doi: 10.1038/leu.2015.124
   PubMed Web of Science ®Google Scholar
• Di MMT, Annamaria G, Gallo CME, et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget. 2013;4(2):242–255.
   PubMedGoogle Scholar
• Rossi M, Amodio N, Di MM, et al. From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario. Curr Drug Targets. 2013;14(10):1144–1149. doi: 10.2174/13894501113149990186
   PubMed Web of Science ®Google Scholar
• Tagliaferri P, Rossi M, Di MM, et al. Promises and challenges of microRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets. 2012;12(7):838–846. doi: 10.2174/156800912802429355
   PubMed Web of Science ®Google Scholar
• Teng Y, Zhao L, Zhang Y, et al. Id-1, a protein repressed by miR-29b, facilitates the TGFβ1-induced epithelial-mesenchymal transition in human ovarian cancer cells. Cellular Physiol Biochem. 2014;33(3):717–730. doi: 10.1159/000358647
   PubMed Web of Science ®Google Scholar
• Wang B, Li W, Liu H, et al. miR-29b suppresses tumor growth and metastasis in colorectal cancer via downregulating Tiam1 expression and inhibiting epithelial-mesenchymal transition. Cell Death Dis. 2014;5(7):e1335–e1335. doi: 10.1038/cddis.2014.304
   PubMed Web of Science ®Google Scholar
• Jia LF, Huang YP, Zheng YF, et al. miR-29b suppresses proliferation, migration, and invasion of tongue squamous cell carcinoma through PTEN–AKT signaling pathway by targeting Sp1. Oral Oncol. 2014;50(11):1062–1071. doi: 10.1016/j.oraloncology.2014.07.010
   PubMed Web of Science ®Google Scholar
• Nicola A, Marzia L, Dina B, et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget. 2012;3(10):1246–1258.
   PubMedGoogle Scholar
• Amodio N, Bellizzi D, Leotta M, et al. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle. 2013;12(23):3650–3662. doi: 10.4161/cc.26585
   PubMed Web of Science ®Google Scholar
• Xie J, Wang J, Zhu B. Genistein inhibits the proliferation of human multiple myeloma cells through suppression of nuclear factor-κB and upregulation of microRNA-29b. Mol Med Rep. 2016;13(2):1627–1632. doi: 10.3892/mmr.2015.4740
   PubMed Web of Science ®Google Scholar
• Jagannathan S, Vad N, Vallabhapurapu S, et al. MiR-29b replacement inhibits proteasomes and disrupts aggresome + autophagosome formation to enhance the antimyeloma benefit of bortezomib. Leukemia. 2015;29(3):727–738. doi: 10.1038/leu.2014.279
   PubMed Web of Science ®Google Scholar
• Takayama K, Suzuki T, Tsutsumi S, et al. Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer. Mol Endocrinol. 2014;28(12):2012–2024. doi: 10.1210/me.2014-1171
   PubMedGoogle Scholar
• Ackermann S, Kocak H, Hero B, et al. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma. BMC Cancer. 2014;14(1):472–416. doi: 10.1186/1471-2407-14-840
   PubMed Web of Science ®Google Scholar
• Choi EJ, Seo EJ, Kim DK, et al. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. Oncotarget. 2016;7(3):3506.
   PubMed Web of Science ®Google Scholar